Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026Non-consolidated (individual)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
In Japan, sales of the company's core agrochemical intermediates declined, but functional intermediates increased substantially on higher demand for new products and other factors. Export sales increased due to higher sales of pharmaceutical intermediates. Operating profit declined, however, due to surging raw material prices and other factors resulting from the situation in the Middle East and other developments.
None ("There are no applicable matters.")
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (individual) |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | ¥2,962 million (YoY +14.3%) |
| Operating profit | ¥61 million (YoY -71.6%) |
| Ordinary income | ¥121 million (YoY -53.5%) |
| Profit attributable to owners of the parent | ¥84 million (YoY -60.9%) |
| Net income per share | ¥64.89 |
| Equity ratio | End of the current fiscal period 70.9 / End of previous period 68.6 |
| Total assets | ¥12,644 million |
| Net assets | ¥8,969 million |
| Cash flows from operating activities | ¥737,901 thousand |
| Cash flows from investing activities | ¥-411,375 thousand |
| Cash flows from financing activities | ¥-610,190 thousand |
| Cash and cash equivalents at end of period | ¥650,900 thousand |
| Full-year earnings forecast | Net Sales ¥6,500 million (YoY +1.0%) / Operating profit To be disclosed at a later date / Ordinary income To be disclosed at a later date / Net income To be disclosed at a later date |
| Revision to Earnings Forecast | None |
| Annual Dividend Forecast | ¥90 → ¥90（0.0%） |
| Regional sales | Region Japan / Net Sales ¥2,767 million / Year-on-year (%) ¥8.7 million, Region Exports / Net Sales ¥194 million / Year-on-year (%) ¥313.8 million |
| Depreciation and amortization | ¥257,584 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income None / Extraordinary loss Loss on disposal of property, plant and equipment ¥11,310 thousand |
| Disclosure regarding the going concern assumption | None ("There are no applicable matters.") |
| Change in accounting policy | Changes due to revisions to standards None / Other changes None / Change in accounting estimate None / Restatement None |
| Availability of Supplementary Financial Results Materials | None |
| Availability of Financial Results Briefing | No (no target participants specified) |
| Issued Shares at Period-End | 1,373,000 |
| Treasury Shares at Period-End | 66,639 |
| Factors Behind Changes in Business Performance | In Japan, sales of the company's core agrochemical intermediates declined, but functional intermediates increased substantially on higher demand for new products and other factors. Export sales increased due to higher sales of pharmaceutical intermediates. Operating profit declined, however, due to surging raw material prices and other factors resulting from the situation in the Middle East and other developments. |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Net sales increased due to higher demand for functional intermediates, on which the company has been focusing through new products, and increased exports of pharmaceutical intermediates. Profit declined, however, due to surging raw material prices and other factors resulting from the situation in the Middle East and other developments.